GlassScriptPhysician profile
Alisha R Bradshaw
NPI 1073846648
$2,671.69
in general payments reported to CMS, 2019-2025
28 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $566 · 2022: $1,132 · 2023: $785 · 2024: $36.51 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $973.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $400.57 | 2021-2023 | Trelegy Ellipta, Shingrix, Nucala |
| Merck Sharp & Dohme LLC | $290.74 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Astrazeneca Pharmaceuticals LP | $236.73 | 2021-2023 | Farxiga |
| Abbvie INC. | $231.16 | 2022-2024 | |
| Pfizer INC. | $183.33 | 2021-2023 | |
| Boston Scientific Corporation | $152.12 | 2025 | Embold Fibered |
| Novo Nordisk INC | $137.43 | 2022-2023 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.37 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $97.76 | 2021-2022 | |
| Amgen INC. | $91.20 | 2021-2023 | Otezla, Repatha |
| Lilly USA, LLC | $90.17 | 2021-2023 | Mounjaro |
| Sumitomo Pharma America, INC. | $76.79 | 2023 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $69.67 | 2022 | |
| Novartis Pharmaceuticals Corporation | $52.74 | 2022 | |
| Abbott Laboratories | $49.43 | 2022-2023 | Freestyle Libre 3 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $48.75 | 2021-2022 | |
| Axsome Therapeutics, INC. | $47.26 | 2023 | Sunosi |
| Sunovion Pharmaceuticals INC. | $42.39 | 2021 | |
| Shield Therapeutics INC | $41.52 | 2022 | |
| Lundbeck LLC | $39.23 | 2021-2022 | |
| Optinose US, INC. | $27.45 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.81 | 2022 | |
| Horizon Therapeutics Plc | $22.22 | 2021 | |
| Astellas Pharma US INC | $18.94 | 2023 | Veozah |
| Teva Pharmaceuticals USA, INC. | $18.18 | 2021 | |
| Exact Sciences Corporation | $17.76 | 2023 | Cologuard Collection Kit |
| Seqirus USA INC | $17.08 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Biohaven Pharmaceuticals, INC. | $13.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alisha Bradshaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.